J. Sträub

1.1k total citations
21 papers, 864 citations indexed

About

J. Sträub is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology. According to data from OpenAlex, J. Sträub has authored 21 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Hepatology. Recurrent topics in J. Sträub's work include Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). J. Sträub is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). J. Sträub collaborates with scholars based in Germany, Spain and United States. J. Sträub's co-authors include Ian Tomlinson, Mohammad Ilyas, Walter F. Bodmer, Aggeliki Papadopoulou, James Wheeler, H. Lamlum, Andrew Rowan, D C Bicknell, Keiichiro Okabe and Georg H. Schmid and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLANT PHYSIOLOGY and Annals of Oncology.

In The Last Decade

J. Sträub

21 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Sträub Germany	8	470	375	329	179	108	21	864
Ahmed Benhasouna United Kingdom	9	428 0.9×	543 1.4×	162 0.5×	452 2.5×	139 1.3×	10	937
Minhong Shen China	16	643 1.4×	370 1.0×	183 0.6×	243 1.4×	93 0.9×	25	1.3k
Lisa E. Humphrey United States	17	498 1.1×	442 1.2×	121 0.4×	112 0.6×	100 0.9×	23	783
M. L. Hanski Germany	8	867 1.8×	269 0.7×	173 0.5×	89 0.5×	67 0.6×	12	1.1k
Archontoula Stoffel United States	12	548 1.2×	259 0.7×	102 0.3×	166 0.9×	80 0.7×	15	826
Maria B. Karpova Switzerland	15	596 1.3×	379 1.0×	240 0.7×	90 0.5×	65 0.6×	31	951
Kristen E. Shannon United States	10	707 1.5×	434 1.2×	146 0.4×	186 1.0×	63 0.6×	10	990
Tarek M.A. Abdel-Fatah United Kingdom	19	767 1.6×	549 1.5×	227 0.7×	350 2.0×	98 0.9×	34	1.1k
Rachel V. Pearline United States	5	756 1.6×	343 0.9×	73 0.2×	168 0.9×	135 1.3×	7	976
Kurt D’Andrea United States	14	452 1.0×	238 0.6×	87 0.3×	235 1.3×	82 0.8×	23	872

Countries citing papers authored by J. Sträub

Since Specialization

Citations

This map shows the geographic impact of J. Sträub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sträub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sträub more than expected).

Fields of papers citing papers by J. Sträub

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Sträub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sträub. The network helps show where J. Sträub may publish in the future.

Co-authorship network of co-authors of J. Sträub

This figure shows the co-authorship network connecting the top 25 collaborators of J. Sträub. A scholar is included among the top collaborators of J. Sträub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Sträub. J. Sträub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Le, Xiuning, Dariusz M. Kowalski, Byoung Chul Cho, et al.. (2021). OFP01.01 Liquid Biopsy to Detect MET Alterations in Patients with Advanced NSCLC: Biomarker Analysis from the VISION Study. Journal of Thoracic Oncology. 16(1). S7–S8. 1 indexed citations

Wu, Yi‐Long, Ying Cheng, Jianfeng Zhou, et al.. (2019). MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up. Journal of Thoracic Oncology. 14(10). S284–S284. 7 indexed citations

Paik, Paul K., Alexis B. Cortot, Enriqueta Felip, et al.. (2019). A phase II trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study. Annals of Oncology. 30. ii66–ii66. 4 indexed citations

Park, K., Enriqueta Felip, Rémi Veillon, et al.. (2019). Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study. Annals of Oncology. 30. ix22–ix23. 6 indexed citations

Yang, James Chih‐Hsin, Barbara Ellers‐Lenz, J. Sträub, Andreas Johne, & Yi‐Long Wu. (2019). INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study. Annals of Oncology. 30. ix181–ix181. 10 indexed citations

Paik, Paul K., Hiroshi Sakai, Rolf Bruns, et al.. (2018). Tepotinib in non-small cell lung cancer (NSCLC) with MET-exon 14 skipping mutations (METex14+) and MET amplification (METamp); A phase II trial in progress. Annals of Oncology. 29. ix169–ix169. 3 indexed citations

Ryoo, Baek‐Yeol, Zhenggang Ren, T.-Y. Kim, et al.. (2018). Phase II trial of tepotinib vs sorafenib for treatment-naïve advanced hepatocellular carcinoma (HCC) in Asian patients. Annals of Oncology. 29. ix58–ix59. 1 indexed citations

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2018). Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib. Annals of Oncology. 29. ix48–ix48. 5 indexed citations

Sakai, Hiroshi, Enriqueta Felip, Alexis B. Cortot, et al.. (2018). Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data. Annals of Oncology. 29. ix152–ix152. 1 indexed citations

10.

Ryoo, Baek‐Yeol, Zhenggang Ren, H. Y. Pan, et al.. (2018). Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC). Annals of Oncology. 29. viii207–viii207. 7 indexed citations

11.

Laeufle, R., Dirk Arnold, Scott Kopetz, et al.. (2018). Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study. Annals of Oncology. 29. viii164–viii164. 1 indexed citations

12.

Decaens, Thomas, C. Barone, Eric Assénat, et al.. (2018). Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC). Annals of Oncology. 29. viii235–viii235. 6 indexed citations

13.

Vansteenkiste, Johan, Fabrice Barlési, Cornelius F. Waller, et al.. (2015). Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology. 26(8). 1734–1740. 64 indexed citations

14.

Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Annals of Oncology. 26(1). 132–140. 89 indexed citations

15.

Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Abituzumab Combined with Cetuximab Plus Irinotecan Versus Cetuximab Plus Irinotecan Alone, as Second-Line Treatment for Patients with KRAS Wild-Type Metastatic Colorectal Cancer: The Poseidon Phase I/Randomized Phase II Trial. Annals of Oncology. 25. ii107–ii107. 1 indexed citations

16.

Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Poseidon Phase I/II Trial: Abituzumab Combined with Cetuximab Plus Irinotecan As Second-Line Treatment for Patients with Kras Wild-Type Metastatic Colorectal Cancer. Annals of Oncology. 25. iv171–iv171. 2 indexed citations

17.

Špıčka, Ivan, et al.. (2010). Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre.. PubMed. 111(3). 207–18. 3 indexed citations

18.

Rowan, Andrew, H. Lamlum, Mohammad Ilyas, et al.. (2000). APC mutations in sporadic colorectal tumors: A mutational “hotspot” and interdependence of the “two hits”. Proceedings of the National Academy of Sciences. 97(7). 3352–3357. 396 indexed citations

19.

Ilyas, Mohammad, J. Sträub, Ian Tomlinson, & Walter F. Bodmer. (1999). Genetic pathways in colorectal and other cancers. European Journal of Cancer. 35(3). 335–351. 214 indexed citations

20.

Okabe, Keiichiro, Georg H. Schmid, & J. Sträub. (1977). Genetic Characterization and High Efficiency Photosynthesis of an Aurea Mutant of Tobacco. PLANT PHYSIOLOGY. 60(1). 150–156. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact